Cost effectiveness of MF59 adjuvanted influenza vaccine in France

被引：0
|
作者：
Chambers, J.
Eijgelshoven, I
Piercy, J.
Wait, S.
机构：
[1] Mapi Values, Boston, MA USA
[2] Mapi Values, Houten, Netherlands
[3] Phimap, Bollington, England
[4] SHW Hlth, London, England
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)69036-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A163 / A164
页数：2
相关论文
共 50 条
  • [21] Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study
    Della Cioppa, Giovanni
    Vesikari, Timo
    Sokal, Etienne
    Lindert, Kelly
    Nicolay, Uwe
    VACCINE, 2011, 29 (47) : 8696 - 8704
  • [22] Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
    De Donato, S
    Granoff, D
    Minutello, M
    Lecchi, G
    Faccini, M
    Agnello, M
    Senatore, F
    Verweij, P
    Fritzell, B
    Podda, A
    VACCINE, 1999, 17 (23-24) : 3094 - 3101
  • [23] Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
    Villa, Marco
    Black, Steven
    Groth, Nicola
    Rothman, Kenneth J.
    Apolone, Giovanni
    Weiss, Noel S.
    Aquino, Ivana
    Boldori, Liana
    Caramaschi, Fausta
    Gattinoni, Antonio
    Malchiodi, Giancarlo
    Crucitti, Antonio
    Della Cioppa, Giovanni
    Scarpini, Elio
    Mavilio, Domenico
    Mannino, Salvatore
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2013, 178 (07) : 1139 - 1145
  • [24] Cost-Effectiveness of Vaccination of Older Adults with an MF59®-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
    Jacob, Jorge
    Biering-Sorensen, Tor
    Holger Ehlers, Lars
    Edwards, Christina H.
    Mohn, Kristin Greve-Isdahl
    Nilsson, Anna
    Hjelmgren, Jonas
    Ma, Wenkang
    Sharma, Yuvraj
    Ciglia, Emanuele
    Mould-Quevedo, Joaquin
    VACCINES, 2023, 11 (04)
  • [25] Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children
    Knuf, Markus
    Leroux-Roels, Geert
    Rumke, Hans
    Rivera, Luis
    Pedotti, Paola
    Arora, Ashwani Kumar
    Lattanzi, Maria
    Kieninger, Dorothee
    Della Cioppa, Giovanni
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (02) : 358 - 376
  • [26] Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy
    Tsai, Theodore F.
    Crucitti, Antonio
    Nacci, Pantaleo
    Nicolay, Uwe
    Della Cioppa, Giovanni
    Ferguson, John
    Clemens, Ralf
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 43 (09) : 702 - 706
  • [27] Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study
    Rubinstein, F.
    Micone, P.
    Bonotti, A.
    Wainer, V.
    Schwarcz, A.
    Augustovski, F.
    Riviere, A. Pichon
    Karolinski, A.
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [28] Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children
    Nolan, Terry
    Bravo, Lulu
    Ceballos, Ana
    Mitha, Essack
    Gray, Glenda
    Quiambao, Beatriz
    Patel, Sanjay S.
    Bizjajeva, Svetlana
    Bock, Hans
    Nazaire-Bermal, Nancy
    Forleo-Neto, Eduardo
    Della Cioppa, Giovanni
    Narasimhan, Vas
    VACCINE, 2014, 32 (46) : 6146 - 6156
  • [29] Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
    Vesikari, Timo
    Forsten, Aino
    Herbinger, Karl-Heinz
    Della Cioppa, Giovanni
    Beygo, Jenny
    Borkowski, Astrid
    Groth, Nicola
    Bennati, Mariaviviana
    von Sonnenburg, Frank
    VACCINE, 2012, 30 (07) : 1388 - 1396
  • [30] Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis
    Domnich, Alexander
    Arata, Lucia
    Amicizia, Daniela
    Puig-Barbera, Joan
    Gasparini, Roberto
    Panatto, Donatella
    VACCINE, 2017, 35 (04) : 513 - 520
12345